Abstracts Archive - Page 153 of 2425 - ACR Meeting Abstracts

Abstract Number: 0303 • ACR Convergence 2024
Phase 2b, Long-term Extension, Dose-ranging Study of Oral JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis: FRONTIER-2
Laura K. Ferris¹, Jerry Bagel², Yu-Huei Huang³, Andrew E. Pink⁴, Stephen K. Tyring⁵, Georgios Kokolakis⁶, Amy M. DeLozier⁷, Daniel Kakaley⁸, Shu Li⁹, Yaung-Kaung Shen¹⁰, Takayuki Ota⁷ and Robert Bissonnette¹¹, ¹University of Pittsburgh, Pittsburgh, PA, ²Psoriasis Treatment Center of Central NJ, East Windsor, NJ, ³Chang Gung Memorial Hospital and Chang Gung University, Linkou, Taoyuan City, Taiwan (Republic of China), ⁴NHS Foundation Trust Great Maze Pond, London, United Kingdom, ⁵Center for Clinical Studies, Webster, TX, ⁶Psoriasis Research and Treatment Center, Department of Dermatology, Venereology and Allergology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁷Janssen Research & Development, LLC, San Diego, CA, ⁸Janssen Scientific Affairs, LLC, Horsham, PA, ⁹Janssen Research & Development, LLC, Spring House, PA/San Diego, CA, ¹⁰Janssen Research & Development, LLC, Spring House, PA, ¹¹Innovaderm Research, Montreal, QC, Canada
Background/Purpose: JNJ-77242113, a targeted oral peptide, inhibits IL-23 signaling by binding the IL-23 receptor. At all doses, JNJ-77242113 showed superior efficacy at Week 16 versus…
Abstract Number: 0525 • ACR Convergence 2024
Assess the Effect of Increasing the Dose of Folic Acid Supplementation in Patients of Rheumatoid Arthritis with Methotrexate Intolerance – A Randomised Controlled Trial
Varun Dhir¹, Harshith Sai Koneti², Aman Sharma³, sanjay jain⁴ and shankar naidu⁵, ¹PGIMER, CHD, INDIA, CHANDIGARH, India, ²PGIMER, Chandigarh, Sangareddy, Telangana, India, ³PGIMER, Chandigarh, India, Chandigarh, Chandigarh, India, ⁴PGIMER, Chandigarh, Chandigarh, India, ⁵PGIMER, Chandigarh, India, Chandigarh, India
Background/Purpose: : Methotrexate (MTX) Intolerance continues to occur in 20-40% patients despite low-dose folic acid (5-10mg per week) supplementation. Would a higher dose of folic…
Abstract Number: 0506 • ACR Convergence 2024
24-week, Post-Marketing Surveillance Analysis of Upadacitinib in Japanese Patients with Rheumatoid Arthritis: The 2024 Interim Report
Takao Fujii¹, Nami Okamoto², Asami Abe³, Michiaki Takagi⁴, Nobunori Takahashi⁵, Atsuo Nakajima⁶, Ayako Nakajima⁷, Shingo Nakayamada⁸, Keiichiro Nishida⁹, Takeshi Kawaberi¹⁰, Naomi Sunaga¹⁰, Yuki Tsujita¹¹, Sumi Chonan¹², Masataka Kuwana¹³ and Yoshiya Tanaka¹⁴, ¹Wakayama Medical University, Wakayama, Japan, ²Osaka Rosai Hospital, Sakai-city, Osaka, Japan, ³Niigata Rheumatic Center, Shibata, Japan, ⁴Yamagata University Faculty of Medicine, Yamagata, Japan, ⁵Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁶Ueno Dialysis Clinic, Tokyo, Japan, ⁷Center for Rheumatic Diseases, Mie University Hospital, Mie, Japan, ⁸The First Department of Internal Medicine, University of Occupational and Environmental Health Japan,, Kitakyushu, Japan, ⁹Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ¹⁰Abbvie GK, Minato-Ku, Tokyo, Japan, ¹¹AbbVie, Minato City Tokyo, Japan, ¹²Abbvie GK, Tokyo, Japan, ¹³Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, ¹⁴Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan
Background/Purpose: Upadacitinib (UPA) was approved in 2020 in Japan for "the treatment of Rheumatoid arthritis (RA) with inadequate response to conventional therapy (including inhibition of…
Abstract Number: 0551 • ACR Convergence 2024
Evaluation of Instruments Assessing Peripheral Arthritis in Spondyloarthritis: An Analysis of the ASAS-perSpA Study
Dafne Capelusnik¹, Anna Molto², Clementina López Medina³, Desiree van der Heijde⁴, Robert Landewé⁵, Maxime Dougados⁶, Joachim Sieper⁷ and Sofia Ramiro⁸, ¹Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ²Groupe Hospitalier Cochin, AP-HP, Paris, France, ³Reina Sofia University Hospital, Cordoba, Spain, ⁴Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ⁵Amsterdam University Medical Center, Meerssen, Netherlands, ⁶Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, ⁷Charité University Medicine Berlin, Berlin, Germany, ⁸Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: The optimal instrument to assess peripheral arthritis and related disease activity in SpA has not yet been identified. In the recent update of the…
Abstract Number: 0542 • ACR Convergence 2024
Impact of Peripheral Arthritis on Disease Activity Outcomes in Patients with Axial Spondyloarthritis, Peripheral Spondyloarthritis and Psoriatic Arthritis. Data from the ASAS-PerSpA Study
Clementina López Medina¹, Sofia Ramiro², Dafne Capelusnik³ and Anna Molto⁴, ¹Reina Sofia University Hospital, Cordoba, Spain, ²Leiden University Medical Center, Bunde, Netherlands, ³Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ⁴Groupe Hospitalier Cochin, AP-HP, Paris, France
Background/Purpose: Patients with spondyloarthritis (SpA) can present with several phenotypes (i.e., axial SpA (axSpA), peripheral SpA (pSpA) and Psoriatic Arthritis (PsA)) and peripheral arthritis can…
Abstract Number: 0431 • ACR Convergence 2024
Reproductive Health in Women with Rheumatic Diseases: Knowledge and Behaviors
Abraham Yair Lujano-Negrete¹, Lorena Perez-Barbosa², Conrado Garcia³, CASSANDRA SKINNER TAYLOR⁴, Jose Hernandez Linas³, Adriana Lobato-Belmonte³, Yesenia Ambriz Murillo⁵, Alfonso Gastelum-Strozzi⁶, Amaranta Manrique de Lara⁷, Ana Rodriguez-Flores⁸, Jesus Cardenas-de la Garza⁹, Marco Maradiaga-Cecena¹⁰, Galilea Rodriguez Orozco¹¹, Anahí Carrazco Chapa¹¹, Dionicio Galarza-Delgado¹² and Ingris del Pilar Pelaez Ballestas³, and Grupo de estudio de salud reproductiva en enfermedades reumáticas autoinmunes en Mexico, ¹Hospital Universitario Jose Eleuterio Gonzalez, UANL, Internal Medicine, Monterrey, Mexico, Monterrey, Mexico, ²Hospital Universitario, UANL, Monterrey, Mexico, ³Hospital General de Mexico Dr. Eduardo Liceaga, Rheumatology, Mexico City, Mexico, Mexico, Mexico, ⁴HOSPITAL UNIVERSITARIO DR JOSE ELEUTERIO GONZALEZ, MONTERREY, Mexico, ⁵Hospital Regional de Morelia, Rheumatology, Morelia, Mexico, Morelia, Mexico, ⁶Instituto de Ciencias Aplicadas y Tecnología, UNAM, Mexico City, Mexico, Monterrey, Mexico, ⁷Hospital General de Mexico Dr. Eduardo Liceaga, Rheumatology, Mexico City, Mexico, Mexico City, Mexico, ⁸Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ⁹Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ¹⁰Hospital General de Culiacan, Rheumatology, Culiacan, Mexico, Culiacan, Sinaloa, Mexico, ¹¹Hospital Universitario Jose Eleuterio Gonzalez, UANL, Rheumatology, Monterrey, Mexico, Monterrey, Mexico, ¹²UANL Hospital Universitario, Monterrey, Nuevo León, Mexico
Background/Purpose: Autoimmune rheumatic diseases (ARDs) affect women during their childbearing years, often leading to pregnancy complications. Effective management of this population requires family planning and…
Abstract Number: 0063 • ACR Convergence 2024
Splicing into Action:Investigating the Role of Alternative Splicing in Rheumatoid Arthritis Neutrophils
Rayan Najjar¹, Noga Rogel² and Tomas Mustelin³, ¹University of Washington, Seattle, ²University of Washinton, Seattle, ³University of Washington, Seattle, WA
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by a variable response to therapies, reflecting its complex and incompletely understood pathogenesis. Emerging research suggests…
Abstract Number: 0470 • ACR Convergence 2024
New Approach for Early and Accurate Diagnosis of Rheumatoid Arthritis-related Interstitial Lung Disease: Matrix Metalloproteinases 7 and 9 as Novel Blood Biomarkers
Veronica Pulito-Cueto¹, Belén Atienza-Mateo², gonzalo Ocejo-Viñals³, Victor M. Mora-Cuesta⁴, David Iturbe-Fernández⁴, Joao Carlos Batista-Liz¹, María Sebastián Mora-Gil⁵, Mónica Renuncio-García⁶, Elena González López³, José M. Cifrián⁷, Ricardo Blanco-Alonso⁸ and Raquel Lopez-mejias¹, ¹IDIVAL, Santander, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, ³Department of Immunology, Marqués de Valdecilla University Hospital (HUMV), Santander, Spain, ⁴Immunopathology Group, Valdecilla Research Institute (IDIVAL) and Department of Pneumology, Marqués de Valdecilla University Hospital (HUMV), Santander, ⁵Immunopathology Group, Valdecilla Research Institute (IDIVAL) and Department of Rheumatology, Marqués de Valdecilla University Hospital (HUMV), Santander, ⁶Division of Immunology, Hospital Universitario Marqués de Valdecilla, Immunopathology Group, IDIVAL, Santander, Spain, ⁷Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. Immunopathology group, IDIVAL, Santander, ⁸Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is one of the main causes of death in rheumatoid arthritis (RA) patients [1]. Early diagnosis of RA-ILD+ is critical…
Abstract Number: 0548 • ACR Convergence 2024
Associations and Impact of Kinesiophobia on Patient Reported Outcomes and Performance-based Mobility Measures in Patients with Axial Spondyloarthritis
David Kiefer¹, Juergen Braun², Uta Kiltz³, Niklas Kolle¹, Lucia Schneider¹, Ioana Andreica⁴, Bjoern Buehring⁵, Philipp Sewerin⁶, Imke Redeker⁷, Styliani Tsiami⁸, Susanne Herbold⁹ and Xenofon Baraliakos⁸, ¹Ruhr-Universität Bochum; Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheuma Praxis, Ruhr-University Bochum, Berlin, Germany, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, ⁴Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ⁵Bergisches Rheuma-Zentrum Wuppertal; Ruhr-Universität Bochum, Wuppertal, Germany, ⁶Ruhr-Universität Bochum, Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷Ruhr Universität Bochum, Bochum, Germany, ⁸Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁹Rheumazentrum Ruhrgebiet, Herne, Herne, Germany
Background/Purpose: Kinesiophobia, defined as the fear of movement, poses a significant barrier to effective rehabilitation, functional recovery, and adequate physical activity. To investigate the impact…
Abstract Number: 0552 • ACR Convergence 2024
Presence of MAIT Cells in Synovial Tissue of Patients with Axial Spondyloarthritis: A Comparative Study
Andre Ramon¹, Philippe Saas², Charline Vauchy³, Maxime Samson² and ERIC TOUSSIROT⁴, ¹Dijon University Hospital, Besançon, France, ²Franche-Comté University, EFS, INSERM, UMR RIGHT, Besançon, France, Besançon, France, ³INSERM CIC-1431, CHU de Besançon, Besancon, France, Besançon, France, ⁴university hospital of BESANCON, besancon, France
Background/Purpose: Mucosal-associated invariant T (MAIT) cells are innate immune T cells that are located at the mucosal barriers. They play a role in mucosal defense,…
Abstract Number: 0325 • ACR Convergence 2024
The Impact of Polymyositis and Dermatomyositis in Patients Hospitalized with Inflammatory Bowel Disease: A Nationwide Inpatient Database Analysis
Pitchaporn Yingchoncharoen¹, Nattanicha Chaisrimaneepan², Jerapas Thongpiya¹, Pojsakorn Danpanichkul¹ and Yanint Raksadawan³, ¹Texas Tech Health Sciences Center, Lubbock, TX, ²Texas Tech University Health Sciences Center, Lubbock, TX, ³Weiss Memorial Hospital, Chicago, IL
Background/Purpose: Polymyositis and dermatomyositis (PM/DM) are subtypes of idiopathic inflammatory myopathies, belonging to the spectrum of polygenic autoimmune diseases Inflammatory bowel disease (IBD), encompassing ulcerative…
Abstract Number: 0376 • ACR Convergence 2024
Preliminary Results of the Ondansetron Pre-medication Trial in Juvenile Idiopathic Arthritis: A Pragmatic Randomized Controlled Trial Nested in the CAPRI Registry
Gaelle Chedeville¹, Heinrike Schmeling², Jean-Philippe Proulx-Gauthier³, Michelle Batthish⁴, Jean Jacques De Bruycker⁵, Brian Feldman⁶, Roberta A Berard⁷, Roxana Bolaria⁸, Amieleena Chhabra⁹, Lily Lim¹⁰, Adam Huber¹¹, Matthew Berkowitz¹², Thomas Loughin¹² and Jaime Guzman¹³, and CAPRI Registry Investigators, ¹The Montreal Children's Hospital, Montreal, QC, Canada, ²University of Calgary, Calgary, AB, Canada, ³CHU de Quebec - Universite Laval, Quebec, QC, Canada, ⁴McMaster Children's Hospital, Hamilton, ON, Canada, ⁵UNIVERSITY OF MONTREAL, Montreal, QC, Montreal, QC, Canada, ⁶Division of Rheumatology, The Hospital for Sick Children; Departments of Pediatrics and Medicine, Faculty of Medicine; The Institute for Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ⁷London Health Sciences Centre, London, ON, Canada, ⁸Victoria Arthritis Center, Victoria, BC, Canada, ⁹University of British Columbia, Penticton, BC, Canada, ¹⁰University of Manitoba, Winnipeg, MB, Canada, ¹¹IWK Health Centre, Halifax, NS, Canada, ¹²Simon Fraser University, Burnaby, BC, Canada, ¹³University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada
Background/Purpose: About 50% of children with Juvenile Idiopathic Arthritis (JIA) receiving methotrexate (MTX) develop MTX intolerance with severe anticipatory nausea/vomiting and avoidance behaviors. Intolerance often…
Abstract Number: 0555 • ACR Convergence 2024
The Effect of Alcohol Consumption on Clinical Outcomes and Structural Damage in Patients with Axial Spondyloarthritis: A Systematic Literature Review and Meta-Analysis
Sinead Maguire¹, Nigil Haroon², Robert Inman³, Melanie Anderson⁴, Evelyne Gendron⁵ and Sindhu R. Johnson⁶, ¹University of Toronto, University Health Network, Schroeder Arthritis Institute, Department of Rheumatology, Toronto, Canada, ²Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴The Institute for Education Research, Library and Information Services, University Health Network, Toronto, ON, Canada, ⁵University of Toronto, University Health Network, Schroeder Arthritis Institute, Department of Rheumatology, Quebec City, QC, Canada, ⁶University of Toronto, Toronto, Canada
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic progressive inflammatory disease characterized by the involvement of the axial skeleton. Alcohol consumption (AC) is a modifiable lifestyle…
Abstract Number: 0563 • ACR Convergence 2024
Clinical Features of Patients with SpA, with or Without IBD: Results from the METEOR Cohort
Manouk de hOoge¹, Pedro M. Machado², Sytske Anne Bergstra³, Maxime Dougados⁴, Clementina López Medina⁵, Victoria Navarro Compán⁶, Diego Benavent⁷, Denis Poddubnyy⁸, Levent kilic⁹, Philippe Carron¹⁰, Dirk Elewaut¹¹, Filip Van den Bosch¹² and Gaelle Varkas¹², ¹Dept. of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium, ²Department of Rheumatology, University College London Hospitals NHS Foundation Trust; and Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust; and Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ³LUMC, Leiden, Netherlands, ⁴Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, ⁵Reina Sofia University Hospital, Cordoba, Spain, ⁶La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, ⁷Rheumatology Department, Hospital Universitari de Bellvitge, Barcelona, Spain, CAMBRILS, Spain, ⁸Charite-Universitatsmedizin Berlin, Berlin, Germany, ⁹Dept. of Rheumatology, Hacettepe University, Ankara, Turkey, Ankara, Turkey, ¹⁰UZ Gent, Gent, Belgium, ¹¹Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ¹²Ghent University Hospital, Ghent, Belgium
Background/Purpose: To investigate clinical features of SpA patients with and without IBD, identifying the patient group that would benefit from initiating therapy with efficacy in…
Abstract Number: 0473 • ACR Convergence 2024
Immune Checkpoint–Induced Arthritis: A Comprehensive Single Cohort Descriptive Analysis from Clinical Evaluation to Histology
NATALUCCI Francesco¹, SOKOLOVA Tatiana², NZEUSSEU TOUKAP Adrien³, GALANT Christine⁴, ABOUBAKAR Frank⁵, BAURAIN Jean-François⁶, CORNELIS Frank⁶, BORBATH Yvan⁷, DUREZ Patrick² and MERIC de BELLEFON Laurent², ¹Sapienza University of Roma, Rheumatology, Department of Clinical, Internistic, Anesthesiological and cardiovascular sciences, Roma, Italy, ²Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium, ³Institut de Recherche Expérimentale et Clinique, Cliniques universitaires Saint-Luc, Université catholique de Louvain, St.-Lambrechts-Woluwe, Belgium, ⁴Department of Pathological Anatomy, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ⁵Division of Pneumology, Cliniques Universitaires Saint-Luc, Brussels, Brussels, Belgium, ⁶Medical Oncology Department, Université Catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium, ⁷Department of Hepato-gastroenterology, Cliniques Universitaires St Luc, Brussels, Belgium
Background/Purpose: The increasing use of Immune Check-Point Inhibitors (ICIs) to treat malignancy focused attention on immune-related adverse events (irAEs). ICIs-induced arthritis is the most common…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].